Loading search results
Making Medication Assisted Treatment Available to Veterans With Opioid Use Disorders at CBOCs Using Telemedicine (PII 18-178)
Sponsor study identifier
Secondary identifiers
OTHER_GRANT · QUERI
observational
12
1 country
2
Study Start
April 1, 2018
Actual (reported)Primary Completion
March 31, 2019
Actual (reported)Study Completion
March 31, 2019
Actual (reported)Medication Assisted Treatment (MAT) of Veterans with Opioid Use Disorder (OUD) decreases mortality and improves treatment follow-up. However, outside of large and/or urban VA medical centers, there are shortages of providers with experience treating OUD and a license to prescribe buprenorphine. This has resulted in decreased access to MAT (buprenorphine/naloxone and injectable naltrexone) at rural CBOCs and increased overdose rates in rural areas. Some individual prescribers have used clinical video teleconferencing (CVT) to overcome geographic barriers and prescribe MAT to Veterans in CBOCs. However, while locally effective, these arrangements are not standardized and are not parts of larger VISN-wide or national VHA strategies. This proposal describes an effective program that the investigators propose to replicate and expand. The program involves increasing prescribing rates of MAT for OUD in CBOCs using telemedicine. The investigators propose to (A) develop materials and procedures for the dissemination of telemedicine delivery of MAT to Veterans at CBOCs and (B) implement telemedicine prescribing of MAT at rural CBOCs in Northern Maine that lack on-site MAT providers. MAT will be prescribed by the VISN 1 Telemental Health Hub, which already provides medication management, psychotherapy, and some MAT to sites in Northern Maine. In later years, the program will be expanded to other VISN 1 CBOCs, and to other TMH Regional Hubs that provide services to wide catchment areas in other VISNs. By building on an existing infrastructure connecting these TMH Regional Hubs to CBOCs and collaborating with other national initiatives (e.g. SCAN ECHO, PDSI, and academic detailing), telemedicine MAT will be rapidly disseminated to Veterans at CBOCs who are at high risk for illness, overdose, and premature death from opioids.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 31, 2019
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 1, 2018
Actual (reported)April 10, 2018
Actual (reported)June 25, 2018
Actual (reported)March 31, 2019
Actual (reported)March 31, 2019
Actual (reported)Population potentially able to benefit from telemedicine MAT
Review Veterans with OUD at CBOC and compare those referred to telemedicine MAT to those not referred. Note that OUD diagnosis may increase over time with better OUD detection
through study completion, up to 1 year
AUDIT-C
The Alcohol Use Disorders Identification Test is a ten-question test developed by a World Health Organization-sponsored collaborative project to determine if a person may be at risk for alcohol abuse problems.
through study completion, up to 1 year
Cost of Telemedicine MAT
cost of time provider and other staff spent in service delivery preparing for and interacting with patients (prompted by CPT-coded encounters). Costs are calculated by multiplying time by personnel costs.
through study completion, up to 1 year
Cost of Training and Implementation
cost of time spent by External and Internal facilitators on training/implementation. Time-spent will be assessed by weekly questions about a list of possible training activities.
through study completion, up to 1 year
Veterans' subjective experience of telemedicine MAT
Veterans with opioid use disorder (OUD) in VA Maine Healthcare System catchment area
CBOC offering medications for opioid use disorder (MOUD) using telemedicine
CBOC not offering medications for opioid use disorder (MOUD) using telemedicine
Veterans with OUD
VA Connecticut Healthcare System West Haven Campus, West Haven, CT
West Haven, Connecticut, 06516, United States
VA Maine Healthcare System
Augusta, Maine, 04330, United States
Brunet N, Moore DT, Lendvai Wischik D, Mattocks KM, Rosen MI. Increasing buprenorphine access for veterans with opioid use disorder in rural clinics using telemedicine. Subst Abus. 2022;43(1):39-46. doi: 10.1080/08897077.2020.1728466. Epub 2020 Feb 20.
Marc I. Rosen, MD
VA Connecticut Healthcare System West Haven Campus, West Haven, CT
12 participants (actual enrollment reported by the registry).
First Submitted
April 10, 2018
First Posted
June 25, 2018
Study Start
April 1, 2018
Actual (reported)Interviews with treated Veterans covering the following topics (9): how came to program, other options considered; experience of intake, of induction onto MAT, of maintenance tele-prescribing visits, of other addiction treatment; good things/not-so-good things about treatment, recommended improvements, how compares to in-person treatment.
through study completion, up to 1 year
Providers' experience of implementing MAT
Key informant interviews after implementation with hub and spoke providers, as described earlier.
through study completion, up to 1 year
Negative toxicology tests
% toxicology tests that are negative for illicit opioids
through study completion, up to 1 year
Number of CBOCs participating in telemedicine MAT
Number of CBOCs utilizing telemedicine MAT
through study completion, up to 1 year
Brief Addiction Monitor-Revised (BAM-R)
Brief Addiction Monitor-Revised (BAM-R) upon intake and two months later.
through study completion, up to 1 year
Number of providers participating in telemedicine MAT
Number at hubs and proportions tele-prescribing MAT; number at spokes seeing Veterans as part of their MAT treatment.
through study completion, up to 1 year
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
March 31, 2019
Actual (reported)Study Completion
March 31, 2019
Actual (reported)Last Updated
March 24, 2020
Record last verified: 2020-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: